MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) announced a new round of equity awards designed to attract and retain talent as the commercial-stage medtech firm expands its workforce and advances its portfolio of soft-tissue reconstruction technologies.
The company said its Board Compensation Committee approved inducement grants covering 30,200 restricted stock units for 17 newly hired employees, along with a stock option award for an additional employee to purchase 25,000 shares. All grants carry a Nov. 10, 2025, award date and were issued under Nasdaq’s Rule 5635(c)(4) inducement exception, which allows companies to provide equity incentives tied directly to employment acceptance.
The stock option carries an exercise price of $1.19 per share, matching the closing price of TELA Bio stock on the grant date. Options vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments over three years. The restricted stock units vest in equal annual installments over four years. All awards require the employees to maintain continuous service with the company.
TELA Bio, which markets surgical solutions that emphasize preservation of a patient’s natural anatomy and minimize reliance on permanent synthetic materials, said the inducement awards are intended to support the company’s ongoing commercial expansion and innovation pipeline.
The company continues to focus on soft-tissue reconstruction technologies aimed at improving clinical outcomes while controlling long-term costs for surgeons and healthcare systems.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.